|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
AstraZeneca’s antibody combination, Evusheld▼ (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19 |
|||||||||||
|
|
|||||||||||
|
17 March 2022
text* |
|||||||||||
|